1861. Clinical Experience with Telavancin for the Treatment of Patients with Bacteremia and Endocarditis: Preliminary results from the Telavancin Observational Use Registry (TOUR™)
Session: Poster Abstract Session: Clinical Study with New Antibiotics and Antifungals
Saturday, October 7, 2017
Room: Poster Hall CD
  • Reilly_IDWeek 2017 Bacteremia Poster_Final_ 26Sep17.pdf (1.7 MB)
  • Background:  Telavancin (TLV) is a lipoglycopeptide antibiotic active against Gram-positive pathogens, including methicillin-sensitive and -resistant Staphylococcus aureus (MSSA and MRSA). S. aureus bacteremia (SAB) can result in serious secondary infections such as infective endocarditis (IE). SAB treatment remains a major challenge and there is a need to identify effective treatments.

    Methods:  The Telavancin Observational Use Registry (TOUR™) is a multicenter chart review study designed to characterize infection types, pathogens, and outcomes of patients treated with TLV in clinical practice. Data from TOUR were used to characterize a subset of patients with bacteremia and IE. Clinical data including patient demographics, pathogens, outcomes, and adverse events (AEs) were analyzed. Clinical outcomes were determined by investigators’ assessment.

    Results:  As of March 31, 2017, data for more than 1000 patients were collected from 46 sites. Of these, 148 patients were treated for bacteremia and/or IE. Among these 148 patients, median age was 59 years (range 18−88 years) and 34% (n = 51) were aged ≥65 years, 55% (n = 81) were male, and 79% (n = 117) were White. The median body mass index was 27.3 kg/m2 (range 13.5−57.9 kg/m2). MRSA was the most commonly isolated pathogen at baseline (57%; n = 84). The median TLV daily dose and duration of treatment were 750 mg (range 250−1500 mg) or 8.9 mg/kg (range 2.9−15.0 mg/kg) and 9 days (range 1−70 days), respectively. Telavancin was used as second-line therapy in 85% (n = 126) of patients, and the majority of patients (78%; n = 115) were treated as inpatients. Overall, 66% (n = 97) of patients were cured or improved to step-down therapy, 9% (n = 13) failed treatment, 14% (n = 21) had an indeterminate clinical outcome at end of therapy (EOT), and 11% (n = 17) had missing or undocumented outcomes. Among the patients who had outcome assessment at EOT (n = 131), 74% were cured or improved to step-down therapy and 10% failed therapy. AEs were reported in 25 patients; 18 reported a serious AE, and 16 had AEs leading to TLV discontinuation.

    Conclusion:  In a real-world setting, once-daily TLV produced positive clinical responses in patients with SAB and/or IE, and may represent an alternative treatment option in these serious infections.

    Joseph Reilly, PharmD, CGP1, Micah Jacobs, MD2, Asma Lat, PharmD3, Anna Osmukhina, PhD3 and Bibiana Castaneda-Ruiz, MD4, (1)Pharmacy, AtlantiCare Regional Medical Center, Atlantic City, NJ, (2)Romano Pontzer And Associates, Pittsburgh, PA, (3)Theravance Biopharma US, Inc., South San Francisco, CA, (4)Theravance Biopharma US Inc., South San Francisco, CA


    J. Reilly, Theravance Biopharma US, Inc.: Scientific Advisor and Speaker's Bureau , Speaker honorarium

    M. Jacobs, Theravance Biopharma US, Inc.: Investigator and Speaker's Bureau , Research support and Speaker honorarium

    A. Lat, Theravance Biopharma US, Inc.: Employee and Shareholder , Salary

    A. Osmukhina, Theravance Biopharma US, Inc.: Employee and Shareholder , RSU, Stock Options and Salary

    B. Castaneda-Ruiz, Theravance Biopharma US, Inc.: Employee and Shareholder , Salary

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.